The ELSPIRE trial evaluated patients with PBC who had an inadequate response or intolerance to UDCA and baseline ALP levels between 1 to 1.67 x ULN.

Miad Maleki, Foundation for Defense of Democracies senior fellow, and Helima Croft, RBC Capital Markets, join 'Power Lunch' ...

Apaluma, which transforms fragmented regulatory records into a unified ecosystem, today announced the closing of its $5.55 ...

Researchers merged data from two randomized controlled trials to examine how antidepressants affect brain tissue in people ...

Bloomberg's most accurate dollar-yen forecaster predicts USD/JPY will reach 170 by 2027. Here's why crypto traders should ...

Photo Credit: iStock A plume of dark smoke above an Ashburn, Virginia, data center during an intense heat wave reflected a ...

SCWorx deploys AI-assisted data management to clean and enrich healthcare supply chain data, reducing errors, waste, and ...

China's biggest airlines enter the peak summer travel season facing a more challenging outlook after warning of heavy ...

Scott Modell, Rapidan Energy CEO, joins 'Squawk on the Street' to discuss the current phase of negotiations with Iran, the ...

Wolfspeed is rated a Sell due to negative gross margins, severe cash burn, and substantial shareholder dilution risks. Read ...

Celestica is well positioned in the AI hardware value chain, with HPS driving significant growth but margins remain ...

Thomas M. Mertens, senior vice president and associate director of research at the Federal Reserve Bank of San Francisco, ...